Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 582.90K | 543.20K | 424.30K | 303.10K | 204.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 582.90K | 543.20K | 424.30K | 303.10K | 204.40K |
| Cost of Revenue | 249.70K | 233.00K | 183.20K | 140.90K | 95.30K |
| Gross Profit | 333.10K | 310.10K | 240.90K | 162.00K | 108.90K |
| SG&A Expenses | 1.08M | 1.48M | 1.80M | 1.99M | 2.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.33M | 1.71M | 1.98M | 2.13M | 2.21M |
| Operating Income | -748.40K | -1.17M | -1.56M | -1.83M | -2.00M |
| Income Before Tax | -1.17M | -1.56M | -1.60M | -1.97M | -2.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.17 | -1.56 | -1.60 | -1.97 | -2.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.17M | -1.56M | -1.60M | -1.97M | -2.12M |
| EBIT | -748.40K | -1.17M | -1.56M | -1.83M | -2.00M |
| EBITDA | -619.00K | -1.10M | -1.55M | -1.82M | -2.00M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 530.54M | 530.54M | 530.54M | 530.54M | 530.54M |
| Average Diluted Shares Outstanding | 530.54M | 530.54M | 530.54M | 530.54M | 530.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |